Alendronate-associated osteonecrosis of the jaws: a review of the main topics
NAGIOS: RODERIC FUNCIONANDO

Alendronate-associated osteonecrosis of the jaws: a review of the main topics

DSpace Repository

Alendronate-associated osteonecrosis of the jaws: a review of the main topics

Show simple item record

dc.contributor.author Paiva Fonseca, Felipe es
dc.contributor.author Santos Silva, Alan Roger es
dc.contributor.author Della Coletta, Ricardo es
dc.contributor.author Vargas, Pablo Agustín es
dc.contributor.author Lopes, Márcio Ajudarte es
dc.date.accessioned 2014-07-04T07:54:36Z
dc.date.available 2014-07-04T07:54:36Z
dc.date.issued 2014 es
dc.identifier.uri http://hdl.handle.net/10550/36871
dc.relation http://www.medicinaoral.com/pubmed/medoralv19_i2_p106.pdf es
dc.source Paiva Fonseca, Felipe ; Santos Silva, Alan Roger ; Della Coletta, Ricardo ; Vargas, Pablo Agustín ; Lopes, Márcio Ajudarte. Alendronate-associated osteonecrosis of the jaws: a review of the main topics. En: Medicina oral, patología oral y cirugía bucal. Ed inglesa, 2014, Vol. 19, No. 2: 106-111 es
dc.subject Odontología es
dc.subject Ciencias de la salud es
dc.title Alendronate-associated osteonecrosis of the jaws: a review of the main topics es
dc.type info:eu-repo/semantics/article en
dc.type info:eu-repo/semantics/publishedVersion en
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.description.abstractenglish Bisphosphonates is a group of inorganic pyrophosphates analogues that suppress bone resorption by inducing osteoclast inactivation, being frequently used for management of diseases affecting bone metabolism, bone metastases and bone tumors. However, since 2003 many cases describing the presence of necrotic bone exposures in the jaws have been described in patients receiving these drugs, what represent a significant complication of bisphosphonates treatment. The overall incidence of bisphosphonate-related osteonecrosis of the jaws is low, ranging from 0.7% to 12%, mainly observed in those patients receiving intravenously treatment. Osteonecrosis of the jaws associated to oral bisphosphonate, particularly alendronate, has also been reported by a number of authors. Considering that alendronate is one of the most used drugs worldwide, specially for treatment of osteoporosis, a better understanding of osteonecrosis of the jaws related to its use and how to manage these patients is extremely important. Therefore, in the current manuscript the authors aim to review the most important topics related to this pathological presentation. es

View       (944.9Kb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics